Tdp1 inhibitor is a novel anticancer drug, an inhibitor of DNA repair enzyme tyrosyl-DNA phosphodiesterase 1 (Tdp1) – one of the main DNA repair enzymes. Its inhibition allows to overcome tumor resistance and improve the efficacy of chemotherapy.

Main advantages (proven in preclinical studies):

−Improves the efficacy of solid tumor chemotherapy by topoisomerase inhibitors (inhibits tumor growth and metastasis);

−Eliminates the dangerous toxic effects of cytostatic drugs (in particular, restores hematopoesis and blood parameters).

−Helps overcome tumor resistance.


Tdp1 inhibitor is intended for use in combination with topoisomerase inhibitors for treating lung cancer, colorectal cancer, ovarian cancer and other malignant tumors.

Current status: Preclinical studies are ongoing.

Intellectual property: patents RU 2627764, US 10399965, PCT application РСТ/RU2017/000543,  patent applications are under review in the EU, China, EAEU.

Investments and commercialization prospects:

– Russia – the project is open for Russian investors/pharmaceutical companies, interested in purchasing the rights to Russian and EAEU markets. Investment requirements are 200M RUB during (up to drug registration). Drug sales start in 2026. Potential sales at Russian and EAEU markets may exceed 1 billion RUB/year.

– Global market – the project is open for venture investors, interested in developing the project at key foreign markets (USA, EU, China, India, etc). Investment requirements are $25M during 2021-2025 (up to the completion of Phase II clinical trials). Potential growth in project value is over $1 billion.